Statins and progression of calcified aortic stenosis.
OBJECTIVE
To review the evidence evaluating the efficacy of statins in reducing the progression of calcified aortic stenosis (AS).


METHODS
MEDLINE, EMBASE, and PubMed were searched (all up to November 2006) for studies evaluating the use of statins to reduce the progression of calcified AS. Search terms included statin, HMG CoA reductase inhibitor, calcified AS, valve stenosis, and calcified stenosis. Additional primary trials were located by searching references noted in review articles.


METHODS
Clinical trials published in the English language were selected for review. Primary efficacy outcomes evaluated were changes in aortic valve measurements, hemodynamic measures of AS, and change in measures of AS severity.


RESULTS
Two prospective clinical trials and 5 retrospective studies were included in this review. All of the retrospective studies demonstrated that statin use was associated with a statistically significant delay in the progression of AS. One prospective observation trial showed benefit of statin use; however, a large, randomized, double-blind, prospective trial showed no benefit of statin use in decreasing the progression of AS.


CONCLUSIONS
An association between statin use and a delay in AS progression has been observed in retrospective studies; however, prospective trials showed conflicting results. Currently, statins cannot be recommended for medical treatment of AS until larger trials are conducted.
Chua
Doson
D
St. Paul's Hospital, Vancouver, BC, Canada. dchua@providencehealth.bc.ca
Kalb
Kelli
K
D001024:Aortic Valve Stenosis / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D002114:Calcinosis / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D018450:Disease Progression; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors